

OCT 16 2003

American HealthCare, Inc.
510(k) for In Vitro Diagnostic Device

K031501

510(k) SUMMARY
(As required by 21.CFR.807.92)

Introduction: According to the requirements of 21 CFR.807.92, the following information provides sufficient data to understand the basis for a determination of substantial equivalence.

Submitted By: American HealthCare, Inc.
304 Park Avenue South
Suite 206
New York, NY 10010

Contact Person: Edward Letko
Phone: 917-402-5900
Fax: 212-202-5388

**Date Summary,
Prepared:** April 18, 2003

Device Name: Propriety Name: EASYGLUCO™
Common Name: Blood Glucose Test System
Classification Name: Class II, 862.1345 Glucose Blood Tester

Predicate Device: We claim substantial equivalence to the LifeScan, Inc.,
OneTouch® Ultra®.

**Device
Description:** The EASYGLUCO™ Monitor is an in vitro diagnostic device designed for measuring the concentration of glucose in whole blood, which is used with the EASYGLUCO™ Test Strips.

The test principle is:

This device is an in vitro diagnostic product intended for the measurement of glucose concentration in human blood. The principle of the test relies upon a specific type of glucose in the blood sample, the dehydrogenase glucose that reacts to electrodes in the test strip. The test strip employs an electrochemical signal generating an electrical current that will stimulate a chemical reaction. This reaction is measured by the Meter and displayed as your blood glucose result.

Intended Use: The EASYGLUCO™ Monitoring System is used by individuals with diabetes. It is for the quantitative measurement of glucose levels in whole blood, as an aid in monitoring the effectiveness of diabetes management in the home and in clinical settings.

American HealthCare, Inc.
510(k) for In Vitro Diagnostic Device

510(k) Summary, Continued

Comparison to

Predicate Device: The Infopia Co., Ltd. EASYGLUCO™ Module is substantially equivalent to the other products in commercial distribution intended for similar use. The most notable, it is substantially equivalent to the currently marketed item, the OneTouch® Ultra® by LifeScan, Inc.

Conclusion:

The EASYGLUCO™ Blood Glucose Monitoring System is substantially equivalent to the following predicate devices:
K024194 – LifeScan, Inc. OneTouch® Ultra®
K984261 – LifeScan, Inc. SURESTEP®
K021513 – Roche Diagnostics Corp. Accu-Chek Advantage



DEPARTMENT OF HEALTH & HUMAN SERVICES

OCT 16 2003

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Mr. Edward Letko
Managing Director
American HealthCare, Inc.
304 Park Avenue South – Suite 206
New York, NY 10010

Re: k031501
Trade/Device Name: EASYGLUCO™
Regulation Number: 21 CFR 862.1345
Regulation Name: Glucose test system
Regulatory Class: Class II
Product Code: NBW; CGA; JJX
Dated: September 8, 2003
Received: September 9, 2003

Dear Mr. Letko:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive style.

Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K 031501

Device Name: EASYGLUCO™

Indications For Use: The EASYGLUCO™ Monitoring System is used by individuals with diabetes. It is for the quantitative measurement of glucose levels in whole blood, as an aid in monitoring the effectiveness of diabetes management in the home and in clinical settings.

Carol C Benson for Jean Cooper, DVM
Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K031501

X OTC use